Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted: Clinical Experience from a Spanish Cohort of Expanded Use.

Júlia Vendrell-Serres Óscar Soto-Angona Amanda Rodríguez-Urrutia Benedetta Inzoli Antonia López González Josep-Antoni Ramos-Quiroga

Published in: Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology (2023)

: Results suggest that esketamine is a safe, effective and rapid-acting option for TRD. More studies are needed to properly assess predictors of response outcome.

Keyphrases

depressive symptoms
sleep quality
case control
loop mediated isothermal amplification